Hercules Offshore Inc (NASDAQ:HERO) Director Thomas R. Bates, Jr. purchased 20,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average price of $3.93 per share, for a total transaction of $78,600.00. Following the completion of the transaction, the director now directly owns 280,000 shares in the company, valued at approximately $1,100,400. Hercules Offshore, Inc. (NASDAQ:HERO) stock performance was 2.28% in last session and finished the day at $4.03. Traded volume was 9.77million shares in the last session and the average volume of the stock remained 4.89million shares. The beta of the stock remained 2.52. Hercules Offshore, Inc. (NASDAQ:HERO) insider ownership is 3.00%.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) rose3.91 percent to $7.44 Wednesday on volume of 1.38million shares. The intra-day range of the stock was $7.04 to $7.55. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has a market capitalization of $769.33million.

Omeros Corporation (NASDAQ:OMER) Director Peter A. Md Demopulos acquired 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $16.20 per share, with a total value of $99,678.60. Following the acquisition, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764. Omeros Corporation (NASDAQ:OMER)’s stock on June 25, 2014 reported a increase of 8.92% to the closing price of $17.47. Its fifty two weeks range is $4.75 -$17.72. The total market capitalization recorded $592.45million. The overall volume in the last trading session was 1.15million shares. In its share capital, OMER has 33.91million outstanding shares.

Insys Therapeutics Inc (NASDAQ:INSY) Director John N. Kapoor bought 5,000 shares of the company’s stock on the open market in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $25.44 per share, for a total transaction of $127,200.00. Following the transaction, the director now directly owns 15,991 shares of the company’s stock, valued at approximately $406,811. On Wednesday, shares of Insys Therapeutics Inc (NASDAQ:INSY) advanced 6.51% to close the day at $30.90. Company return on investment (ROI) is 52.10% and its monthly performance is recorded as 17.76%. Insys Therapeutics Inc (NASDAQ:INSY) quarterly revenue growth is -31.65%.

New Mountain Finance Corp. (NASDAQ:NMFC) CAO Adam Weinstein acquired 3,500 shares of New Mountain Finance Corp. stock on the open market in a transaction that occurred on Monday, June 16th. The stock was purchased at an average cost of $14.35 per share, for a total transaction of $50,225.00. Following the completion of the acquisition, the chief accounting officer now directly owns 29,134 shares in the company, valued at approximately $418,073. New Mountain Finance Corp. (NYSE:NMFC) stock performance was 0.77% in last session and finished the day at $14.45. Traded volume was 547,250.00million shares in the last session and the average volume of the stock remained 527.26K shares. The beta of the stock remained 0.06. New Mountain Finance Corp. (NYSE:NMFC) insider ownership is 0.80%.